Aubagio(teriflunomide)
Aubagio (teriflunomide) is a small molecule pharmaceutical. Teriflunomide was first approved as Aubagio on 2012-09-12. It is used to treat relapsing-remitting multiple sclerosis in the USA. It has been approved in Europe to treat multiple sclerosis and relapsing-remitting multiple sclerosis. The pharmaceutical is active against dihydroorotate dehydrogenase (quinone), mitochondrial.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Aubagio (generic drugs available since 2018-09-04)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Teriflunomide
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
AUBAGIO | Sanofi | N-202992 RX | 2012-09-12 | 2 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
aubagio | New Drug Application | 2020-11-19 |
teriflunomide | ANDA | 2023-06-17 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
relapsing-remitting multiple sclerosis | EFO_0003929 | D020529 | — |
Agency Specific
FDA
EMA
Expiration | Code | ||
---|---|---|---|
TERIFLUNOMIDE, AUBAGIO, SANOFI AVENTIS US | |||
2024-10-30 | PED | ||
2024-04-30 | M-61 | ||
TERIFLUNOMIDE, TERIFLUNOMIDE, ACCORD HLTHCARE | |||
2023-09-08 | PC | ||
TERIFLUNOMIDE, TERIFLUNOMIDE, AMNEAL PHARMS CO | |||
2023-09-08 | PC | ||
TERIFLUNOMIDE, TERIFLUNOMIDE, APOTEX | |||
2023-09-08 | PC | ||
TERIFLUNOMIDE, TERIFLUNOMIDE, AUROBINDO PHARMA | |||
2023-09-08 | PC | ||
TERIFLUNOMIDE, TERIFLUNOMIDE, GLENMARK PHARMS | |||
2023-09-08 | PC | ||
TERIFLUNOMIDE, TERIFLUNOMIDE, SANDOZ | |||
2023-09-08 | PC | ||
TERIFLUNOMIDE, TERIFLUNOMIDE, TEVA PHARMS USA | |||
2023-09-08 | PC | ||
TERIFLUNOMIDE, TERIFLUNOMIDE, WATSON LABS TEVA | |||
2023-09-08 | PC | ||
TERIFLUNOMIDE, TERIFLUNOMIDE, ZYDUS PHARMS | |||
2023-09-08 | PC |
HCPCS
No data
Clinical
Clinical Trials
48 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Multiple sclerosis | D009103 | EFO_0003885 | G35 | 1 | 7 | 14 | 4 | 2 | 28 |
Relapsing-remitting multiple sclerosis | D020529 | EFO_0003929 | — | — | 9 | 1 | 3 | 13 |
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Celiac disease | D002446 | EFO_0001060 | K90.0 | 1 | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | 1 | — | — | — | — | 1 | ||
Renal insufficiency | D051437 | HP_0000083 | N19 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Medication adherence | D055118 | EFO_0006344 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | TERIFLUNOMIDE |
INN | teriflunomide |
Description | Teriflunomide is an enamide obtained by formal condensation of the carboxy group of (2Z)-2-cyano-3-hydroxybut-2-enoic acid with the anilino group of 4-(trifluoromethyl)aniline. Used for the treatment of relapsing forms of multiple sclerosis and rheumatoid arthritis. It has a role as an EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor, a tyrosine kinase inhibitor, a hepatotoxic agent, a drug metabolite and a non-steroidal anti-inflammatory drug. It is a nitrile, an enol, an aromatic amide, an enamide, a member of (trifluoromethyl)benzenes and a secondary carboxamide. |
Classification | Small molecule |
Drug class | — |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | C/C(O)=C(\C#N)C(=O)Nc1ccc(C(F)(F)F)cc1 |
Target
Agency Approved
DHODH
DHODH
Alternate
No data
Variants
Clinical Variant
No data
Financial
Aubagio - Sanofi
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,232 documents
View more details
Safety
Black-box Warning
Black-box warning for: Aubagio, Teriflunomide
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
946 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more